ORIC-259
Asset
Small molecule mRNA degrader targeting CIP2A
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- CIP2A
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Cancer
Preclinical, globenewswire.com, 5 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners2
- Evidence for its targets1
- Competitors11
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.